Entry into a Material Definitive Agreement

On June 1, 2020, Humanigen, Inc. (the "Company") reported that entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors (the "Investors") to complete a private placement (the "Private Placement") of the Company’s common stock, par value $0.001 per share (the "Common Stock") (Filing, 8-K, Humanigen, JUN 1, 2020, View Source [SID1234560838]). The closing of the Private Placement occurred on June 2, 2020 (the "Closing Date"). At the closing, the Company issued and sold 82,528,718 shares of Common Stock (the "Shares") at a purchase price of $0.87 per share, for aggregate gross proceeds of approximately $71.8 million. The purchase price represented a 7% discount from the volume weighted average price of the Common Stock over the prior 20 trading days ending May 29, 2020. Effective upon completion of the Private Placement, the Company has an aggregate of 208,931,973 shares of Common Stock outstanding.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On the Closing Date, the Company and the Investors also entered into a registration rights agreement (the "Registration Rights Agreement") pursuant to which the Company agreed to prepare and file a registration statement (the "Resale Registration Statement") for the resale of the Shares with the Securities and Exchange Commission (the "SEC"), within 10 business days of the Closing Date, and use reasonable best efforts to have the Resale Registration Statement declared effective by the SEC at the earliest possible date. Subject to certain limitations and an overall cap, the Company may be required to pay liquidated damages to the investors at a rate of 2% of the invested capital for each instance in which:

·The Company fails to make the initial filing of the Resale Registration Statement by June 16, 2020;
·
The Company fails to cause the Resale Registration Statement to be declared effective prior to the earlier of (i) three business days after the SEC informs the Company that no review of the Resale Registration Statement will be made or that the SEC has no further comments on the Resale Registration Statement (but subject to the last sentence of Section 9.7 of the Purchase Agreement), or (ii) July 2, 2020 (or August 31, 2020 if the Staff has informed the Company that it will be reviewing or monitoring the Resale Registration Statement); or

·The prospectus included in the Resale Registration Statement ceases to be available for use by the investors for more than 30 consecutive days or more than 50 days in any 12-month period.

The Purchase Agreement also provides that the Company will use its commercially reasonable efforts to achieve a listing of the Common Stock on a national securities exchange, subject to certain limitations set forth in the Purchase Agreement. The Company’s ability to obtain approval of the listing of the Common Stock on a national securities exchange will require the Company to satisfy a number of conditions, including the effectiveness of the Resale Registration Statement, the Company’s ability to obtain certain stockholder and third party consents and approvals, and the Company’s ability to meet certain listing criteria including a minimum stock price and total value of public float. Accordingly, the Company may not be able to achieve a listing of the Common Stock on a national securities exchange in any particular time frame or at all.

Genelux Announces Formation of Clinical Advisory Board on Gynecologic Cancers

On June 4, 2020 Genelux Corporation, a privately-held, clinical-stage immuno-oncology company, reported that it has formed a Clinical Advisory Board (CAB) on gynecologic cancers that will guide clinical development of its lead clinical-stage candidate, Olvi-Vec (olvimulogene nanivacirepvec) (Press release, Genelux, JUN 4, 2020, View Source [SID1234560855]). Genelux has completed enrollment of VIRO-15, a multi-center, open-label, Phase 2 study (NCT02759588) testing Olvi-Vec in platinum-resistant/refractory ovarian cancer and is in the follow up phase of the trial.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are honored and extremely fortunate to have assembled this team of gynecologic oncology experts, all of whom are preeminent clinicians, extensively-published authors and renowned lecturers, as well as leaders of gynecologic cancer societies and prestigious editorial boards," said Thomas Zindrick, President and CEO of Genelux. "Following our recently-announced productive Type C meeting with the FDA, the appointment of our CAB members comes at a pivotal time in our Company’s evolution, and we look forward to their insight and expertise in helping the company advance our promising Olvi-Vec program into Phase 3."

Abbreviated biographies of Genelux’s inaugural CAB members are as follows:

Chair: Robert W. Holloway, MD – Medical Director, Gynecologic Oncology, AdventHealth Cancer Institute, Orlando, Florida

Dr. Holloway is the principal investigator for VIRO-15 and has served on several committees of the Society of Gynecologic Oncology (SGO), including its Board of Directors. He is a Fellow of the American College of Surgeons and founding member of the Global Robotics Institute at AdventHealth, Orlando. Dr. Holloway has authored or coauthored more than 100 peer-reviewed articles. Dr. Holloway completed medical school at Vanderbilt University Medical Center, residency at University of Alabama, Birmingham, and fellowship at Georgetown University Hospital.
Robert L. Coleman, MD – Gynecologic Oncology, Chief Scientific Officer, US Oncology Research, The Woodlands, Texas

Dr. Coleman currently serves on the Board of Directors of Gynecologic Oncology Group and is a Director of GOG-Partners. In addition, he has served as President of SGO and as a Council member and Secretary Treasurer for the International Gynecologic Cancer Society, for which he is President-Elect (2020-2022). Dr. Coleman has authored or coauthored more than 300 peer-reviewed articles. Dr. Coleman completed medical school at Creighton University School of Medicine, residency at Northwestern University Medical Center, and gynecologic oncology fellowship at the University of Texas MD Anderson Cancer Center. He served as Professor and Ann Rife Chair in Gynecology at University of Texas, M.D. Anderson Cancer Center and Executive Director, M.D. Anderson Cancer Network Research until April 2020.
Thomas J. Herzog, MD – Deputy Director of the University of Cincinnati Cancer Institute and Vice-Chair of Quality and Safety for Obstetrics and Gynecology, University of Cincinnati College of Medicine Cincinnati, Ohio

Dr. Herzog is Secretary Treasurer and Associate Director of the GOG Foundation. In addition, he has served on the leadership board or council of SGO, the Foundation for Women’s Cancer, Board of Governors for the American College of Surgeons, American Board of Obstetrics and Gynecology, and International Gynecologic Cancer Society. Dr. Herzog has authored/co-authored 290+ peer-reviewed articles. Dr. Herzog graduated from the University of Cincinnati College of Medicine and completed his residency at Good Samaritan Hospital in Cincinnati and a fellowship in gynecologic oncology at the Washington University School of Medicine, St. Louis, MO.
Alberto A. Mendivil, MD – Co-Director, Gynecologic Oncology, Hoag Memorial Hospital Presbyterian, Newport Beach, California

Dr. Mendivil, site principal investigator for VIRO-15, serves as Co-Director, Gynecologic Oncology and Complex Pelvic Surgery, Hoag Hospital. He has authored or coauthored more than 40 peer-reviewed publications and has been the principal investigator or site sub-investigator on 20+ clinical trials. Dr. Mendivil received his medical degree from the University of Utah School of Medicine and completed internship and residency training in Obstetrics and Gynecology at the University of California, Irvine, and fellowship training in gynecologic oncology at the University of North Carolina, Chapel Hill.
David M. O’Malley, MD – Professor and Division Director, Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, Columbus, Ohio

Dr. O’Malley is the clinical trial advisor/lead for ovarian cancer within GOG Partners, a committee member for the NCI Gynecologic Cancer Steering Committee’s Ovarian Task Force and the NRG Oncology (Ovarian Cancer and Developmental Therapeutics Groups), and a panel member of the national Comprehensive Cancer Network Guidelines for Ovarian Cancer. He has authored 130+ peer-reviewed publications. Dr. O’Malley received his medical degree from the Wayne State University School of Medicine, and completed his residency at Case Western Reserve University (MetroHealth) and the Cleveland Clinic Foundation, and gynecologic oncology fellowship at Yale University.
About Olvimulogene Nanivacirepvec (Olvi-Vec)
Olvi-Vec is a proprietary, non-pathogenic oncolytic vaccinia virus, modified to increase its safety, tumor selectivity and anti-tumor activity. Virus-mediated oncolysis results in immunogenic cell death and triggers immune activation and memory for long-term immunotherapy against cancer. Clinical results in more than 150 subjects have shown Olvi-Vec is well tolerated with documented clinical benefits.

Myriad Genetics Announces Publication of a Prospective Clinical Study of the EndoPredict® Test in Women with Early-Stage Breast Cancer

On June 4, 2020 Myriad Genetics, Inc. (NASDAQ: MYGN, "Myriad" or the "Company"), a global leader in molecular diagnostics and precision medicine, reported the publication of a prospective study demonstrating that the EndoPredict test predicts which patients with ER+, HER2- early-stage breast cancer will benefit from neoadjuvant therapy (Press release, Myriad Genetics, JUN 4, 2020, View Source [SID1234561737]). The article titled, "The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial," appeared online in the European Journal of Cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This study demonstrated that the EndoPredict (EP) test predicted response to neoadjuvant chemotherapy or neoadjuvant endocrine therapy in women with ER+, HER2 negative early-stage breast cancer," said Peter Dubsky, M.D., lead author, speaking on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG). "Based on these findings and prior studies, we are confident the EndoPredict test can add valuable information to aid in personalized treatment selection in neoadjuvant therapy and provides an important basis for future design of neoadjuvant clinical trials."

The primary objective of this prospective study was to test the predictive value of the EndoPredict test regarding tumor response after neoadjuvant chemotherapy (NaCT) or neoadjuvant endocrine therapy (NET) within the ABCSG-34 trial. The analysis included data from 217 women with HR+ breast cancer. Of these, 134 patients were assigned to receive NaCT (eight cycles of anthracycline/taxane) according to aggressive clinico-pathologic tumor features. The remaining 83 patients were clinically identified as having luminal A-like types of breast cancer and were assigned to receive NET (six months of letrozole). The primary endpoint was residual cancer burden RCB0/I (i.e., good tumor response) vs. RCB II/III (i.e., poor tumor response) at time of surgery.

In the neoadjuvant chemotherapy group, 125 patients had high EP scores and nine had a low EP score. The results show that 26.4 percent of those with a high score showed a good tumor response (RCB0/I) to neoadjuvant chemotherapy, while all patients with a low score showed only a poor tumor response (Table 1). In the "luminal A" group receiving neoendocrine therapy, 39 patients had a high EP score and 44 had a low EP score. The results show that 27.3 percent of those with a low EndoPredict score and 7.7 percent with a high score achieved excellent tumor response (RCB0/I) to neoendocrine therapy (Table 1).

Table. 1

EndoPredict
Low Score

EndoPredict
High Score Predictive Performance
EndoPredict Score
(p-value)
Response to Neoadjuvant Chemotherapy

0.0

%

26.4

%

p=0.0001
Response to
Endocrine Therapy 27.3 % 7.7 % P=0.015
"In this prospective study, we demonstrated that the EndoPredict test is a useful tool pre-operatively," said Ralf Kronenwett, M.D., director of International Medical Affairs at Myriad. "In two distinct ER-positive, HER2-negative cohorts selected by clinicians to receive neoadjuvant chemotherapy or neoadjuvant endocrine therapy, EndoPredict identified patients with poor neoadjuvant treatment response. Clinicians can use information to determine who might forgo these therapies prior to surgery."

About EndoPredict
EndoPredict is a second-generation, 12-gene molecular prognostic test for patients diagnosed with breast cancer. The test provides vital information that helps clinicians devise personalized treatment plans for their patients. EndoPredict has been validated in more than 4,000 patients with node-negative and node-positive cancer and has been used clinically in more than 20,000 patients. In contrast to first-generation multigene prognostic tests, EndoPredict detects the likelihood of late metastases (i.e., metastasis formation after more than five years) and, therefore, can guide treatment decisions regarding the need for chemotherapy, as well as extended anti-hormonal therapy. Accordingly, therapy decisions backed by EndoPredict confer a high level of diagnostic safety. For more information, please visit: www.endopredict.com.

Alligator Bioscience and Scandion Oncology sign preclinical agreement to explore combination therapies for chemotherapy and immuno-oncology

On June 4, 2020 Alligator Bioscience (Nasdaq Stockholm: ATORX) and Scandion Oncology (Spotlight, Sweden: SCOL), reported signing of a collaboration agreement (Press release, Alligator Bioscience, JUN 4, 2020, View Source [SID1234560822]). The two companies have agreed to explore the anti-tumor efficacy of the CD40 antibody mitazalimab (Alligator Bioscience) in combination with SCO-101 (Scandion Oncology) as an addition to chemotherapy in resistant preclinical tumor models. The expectation is that SCO-101 will revert chemotherapy resistance and thereby further strengthening the anti-tumor effects of mitazalimab.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Immuno-oncology (IO) drugs have proven very effective in subsets of cancer patients. Recently, data from large clinical trials have shown that the combination of IO drugs and standard chemotherapy results in additive anti-tumor effects and more durable remissions in cancer patients. However, many cancers develop resistance to chemotherapy and consequently, no additive effects will be expected in these patients.

The Alligator Bioscience drug candidate mitazalimab enhances presentation of antigens released by cancer cells and is thought to be beneficial in combination with chemotherapy, where large amounts of antigens are being released by dying tumor cells. Scandion Oncology’s drug candidate SCO-101 acts by blocking resistance mechanisms in cancer cells, allowing chemotherapy to kill previously resistant cancer cells. Thereby, SCO-101 would restore the release of antigens and re-activate the anti-cancer effects of the IO drugs.

"This collaboration will further validate mitazalimab’s potential in combination therapy with diverse chemotherapeutic agents, as well as the power of SCO-101 as a solution to the widespread issue of chemoresistance," said Per Norlén, CEO of Alligator Bioscience.

"This is a dream scenario for Scandion Oncology. Combinations between SCO-101, chemotherapy and an IO drug like mitazalimab could easily become the future of anti-cancer therapy" says Nils Brünner, CEO of Scandion Oncology.

Qualigen Therapeutics Receives U.S. Patent Notice of Allowance for its STARS™ Technology

On June 4, 2020 Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (Qualigen or the Company) reported that the United States Patent and Trademark Office has issued a Notice of Allowance for a U.S. patent, which will be issued to the Company, titled "Devices and Methods for On-Line Whole Blood Treatment" regarding the Company’s Selective Target Antigen Removal System (STARS) technology (Press release, Qualigen, JUN 4, 2020, View Source [SID1234560856]). STARS is a DNA/RNA-based treatment for the removal of viral and tumor-produced compounds from a patient’s blood. The STARS technology utilizes a filtration cartridge designed for use in a standard dialysis machine, and contains aptamer-coated microparticles that bind to specific agents in circulating blood for targeted removal.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"When issued, this new U.S. patent will further protect our proprietary STARS technology and enhance our overall intellectual property portfolio," said Michael Poirier, President, Chief Executive Officer and Chairman of Qualigen. "Qualigen’s strategy to fighting disease is to ‘Detect, Destroy, Remove’. Supporting the Remove component, the STARS development program utilizes technology and expertise from our FastPack point-of-care diagnostic system, which has been in use worldwide for nearly 20 years for the detection of cancer and other diseases. We look forward to advancing STARS as a target and removal therapy for multiple diseases and other health conditions."

The Company plans to develop STARS for cancer applications to remove inflammatory factors and inhibitory checkpoints from blood, thus reducing pain and helping the body’s immune system fight the disease, as well as for infectious diseases to remove viruses and other foreign agents. STARS technology and key components utilize membranes coated with target capture reagents. STARS is in the early stages of development and has demonstrated promising proof-of-concept results in the Company’s in vitro studies.